Shigeyuki Nishinaka
Director/Board Member presso MYOVANT SCIENCES LTD.
Profilo
Shigeyuki Nishinaka is currently a Director at Sumitomo Pharma America, Inc., a Director at Meltin MMI KK, a Director at Myovant Sciences Ltd., a Director at Urovant Sciences, Inc., an Independent Director at Urovant Sciences Ltd., a Director at Sumitovant Biopharma, Inc., and a Managing Executive Officer at Sumitomo Pharma Co., Ltd.
He previously worked as a Director General-Inspection Bureau at Financial Services Agency.
He holds a doctorate degree from Hiroshima University.
Posizioni attive di Shigeyuki Nishinaka
Società | Posizione | Inizio |
---|---|---|
SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | 01/01/2009 |
UROVANT SCIENCES LTD. | Director/Board Member | 27/12/2019 |
MYOVANT SCIENCES LTD. | Director/Board Member | 22/10/2022 |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Director/Board Member | - |
Meltin MMI KK
Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Director/Board Member | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Director/Board Member | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Director/Board Member | 01/12/2019 |
Precedenti posizioni note di Shigeyuki Nishinaka
Società | Posizione | Fine |
---|---|---|
Financial Services Agency | Corporate Officer/Principal | - |
Formazione di Shigeyuki Nishinaka
Hiroshima University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
SUMITOMO PHARMA CO., LTD. | Health Technology |
Aziende private | 7 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Financial Services Agency | Government |
Meltin MMI KK
Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Health Technology |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Shigeyuki Nishinaka